login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NUVATION BIO INC (NUVB) Stock News
USA
- NYSE:NUVB -
US67080N1019
-
Common Stock
5.22
USD
+0.07 (+1.36%)
Last: 10/31/2025, 8:04:02 PM
5.18
USD
-0.04 (-0.77%)
After Hours:
10/31/2025, 8:04:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NUVB Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Nuvation Bio
Nuvation Bio to Participate in Upcoming Investor Conferences
3 days ago - By: Zacks Investment Research
- Mentions:
MDXG
MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates
9 days ago - By: Nuvation Bio
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
12 days ago - By: Nuvation Bio
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
a month ago - By: Benzinga
4 Analysts Assess Nuvation Bio: What You Need To Know
2 months ago - By: Benzinga
Analyst Expectations For Nuvation Bio's Future
24 days ago - By: New York Stock Exchange
- Mentions:
ESRT
NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street
a month ago - By: The Motley Fool
- Mentions:
SPGI
JEF
Why Nuvation Bio Stock Is Skyrocketing Today
a month ago - By: Nuvation Bio
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
a month ago - By: Nuvation Bio
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
2 months ago - By: Nuvation Bio
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
2 months ago - By: Nuvation Bio
Nuvation Bio to Participate in Upcoming Investor Conferences
2 months ago - By: Zacks Investment Research
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?
3 months ago - By: The Motley Fool
NUVB Sales Jump 1,043% on Drug Launch
3 months ago - By: Zacks Investment Research
- Mentions:
LCTX
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: Nuvation Bio
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Zacks Investment Research
- Mentions:
ACAD
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
3 months ago - By: Nuvation Bio
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
3 months ago - By: Nuvation Bio
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
4 months ago - By: Yahoo Finance
- Mentions:
GS
NUVL
JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans
4 months ago - By: Nuvation Bio
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
4 months ago - By: Yahoo Finance
- Mentions:
TSLA
OVID
Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?
5 months ago - By: Yahoo Finance
- Mentions:
PFE
REGN
BX
SUNN
...
US pharma bets big on China to snap up potential blockbuster drugs
5 months ago - By: Nuvation Bio
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
5 months ago - By: Nuvation Bio Inc.
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting
6 months ago - By: Nuvation Bio Inc.
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
6 months ago - By: Nuvation Bio Inc.
Nuvation Bio to Participate in Upcoming Investor Conferences
6 months ago - By: Yahoo Finance
- Mentions:
JNJ
MDT
WGRX
LLY
...
Is Johnson & Johnson (JNJ) the Best Medical Device Stock to Buy Now?
6 months ago - By: Yahoo Finance
- Mentions:
ABT
WGRX
LLY
NVDA
...
Why Abbott Laboratories (ABT) is Among the Best Medical Device Stocks to Buy Now
6 months ago - By: Yahoo Finance
- Mentions:
NCLH
ESI
CTLP
BMRN
...
Norwegian Cruise Line Holdings Ltd. (NCLH): Among Billionaire Quants’ Two Sigma’s Stock Picks with Huge Upside Potential
Please enable JavaScript to continue using this application.